AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Glytec and AdventHealth Highlight the Broad Impact of Electronic Glycemic Management at HIMSS 2020

March 3, 2020 GMT

WALTHAM, Mass.--(BUSINESS WIRE)--Mar 3, 2020--

Glytec, the only provider of insulin management software across the continuum of care, today announced it will highlight the broad impact that electronic glycemic management systems (eGMS) have on improving patient outcomes and reducing costs at the 2020 HIMSS Global Health Conference. During the event, Glytec is participating in the Value of Healthcare Pavilion (Booth 680 in Hall A), where attendees can hear research about the impact of eGMS in inpatient settings during a session from Dr. Richard Pratley, Medical Director of the AdventHealth Diabetes Institute, at 3:45 p.m. on Wednesday, March 11.

On average, one-third of patients require insulin therapy to manage blood glucose levels during a hospital stay. Yet, a vast majority of inpatient settings still rely on dated paper protocols and sliding scale initiatives to titrate insulin. Dr. Pratley will present evidence of the impact improper insulin management can have on the cost and quality of care, including observations from a 12-month study across seven hospitals and more than 46,000 patients. The study found that hospitalized patients who experience severe hypoglycemia incur $10,405 of excess cost, a 61.5% higher readmission rate and a 6.6-day longer stay.

Dr. Pratley will also address strategies for improving outcomes through better glycemic management and the role an electronic decision support system can play. For example, AdventHealth Waterman, a 269-bed community hospital in central Florida, reduced errors, improved utilization, lowered rates of hypoglycemia and realized cost savings of $350,000 after implementing Glytec’s Glucommander – an advanced FDA-cleared eGMS. The hospital experienced a 96.8% improvement in incidence of severe hypoglycemia with the root cause of insulin stacking and 87.0% improvement in incidence of severe hypoglycemia with the root cause of failure to adjust insulin doses.

“Most people have a friend or loved one living with diabetes, so they’re aware of the challenge with managing blood glucose levels on a daily basis and the severe impacts that poor management can have,” said Robby Booth, Co-founder and Sr. VP of Research and Development at Glytec. “But there’s a general lack of awareness around the fact that glucose management is such an important aspect of care for so many people in a hospital – whether they have diabetes or not. The work AdventHealth has done brings important light to this issue by quantifying the positive impacts of better glucose management, and we’re thrilled to be able to help share it with HIMSS attendees.”

To learn more about Glytec and the impact that insulin management software can have at health systems, including AdventHealth, stop by the Value of Healthcare Pavilion (booth 680 in Hall A) at HIMSS 2020 from March 9-13 in Orlando, Florida, or visit www.glytecsystems.com.

About Glytec
Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes. For more information, follow Glytec on Twitter (@Glytec ) or LinkedIn, or visit www.GlytecSystems.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200303005222/en/

CONTACT: Mike Reilly

fama PR for Glytec

617-986-5008

Glytec@famapr.com

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY DIABETES MEDICAL DEVICES HEALTH PHARMACEUTICAL

SOURCE: Glytec

Copyright Business Wire 2020.

PUB: 03/03/2020 09:01 AM/DISC: 03/03/2020 09:01 AM

http://www.businesswire.com/news/home/20200303005222/en